Staar Surgical CO STAA
We take great care to ensure that the data presented and summarized in this overview for STAAR SURGICAL CO is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding STAA
View all-
Broadwood Capital Inc New York, NY10.8MShares$193 Million20.84% of portfolio
-
Black Rock Inc. New York, NY7.49MShares$133 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.86MShares$104 Million0.0% of portfolio
-
State Street Corp Boston, MA2.05MShares$36.5 Million0.0% of portfolio
-
Resona Asset Management Co.,Ltd. Koto Ku,Tokyo, M01.5MShares$26.7 Million0.22% of portfolio
-
Geode Capital Management, LLC Boston, MA1.17MShares$20.9 Million0.0% of portfolio
-
Baillie Gifford & CO1.15MShares$20.5 Million0.02% of portfolio
-
Armistice Capital, LLC New York, NY872KShares$15.5 Million0.3% of portfolio
-
Dimensional Fund Advisors LP Austin, TX853KShares$15.2 Million0.01% of portfolio
-
American Capital Management Inc New York, NY848KShares$15.1 Million0.77% of portfolio
Latest Institutional Activity in STAA
Top Purchases
Top Sells
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Insider Transactions at STAA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 14
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 14
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
36,532
+0.32%
|
$547,980
$15.49 P/Share
|
Feb 13
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 13
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
115,282
+1.01%
|
$1,729,230
$15.84 P/Share
|
Feb 12
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Feb 12
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
259,616
+0.78%
|
$3,634,624
$14.89 P/Share
|
Jan 16
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 16
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
8,221
+0.08%
|
$172,641
$21.5 P/Share
|
Jan 14
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Jan 14
2025
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
21,155
+0.19%
|
$444,255
$21.46 P/Share
|
Jan 03
2025
|
Thomas G Frinzi President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,775
-13.25%
|
$258,600
$24.54 P/Share
|
Dec 18
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Dec 18
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
23,000
+0.21%
|
$552,000
$24.33 P/Share
|
Dec 17
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Dec 17
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
3,700
+0.03%
|
$88,800
$24.58 P/Share
|
Dec 16
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
Dec 16
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
53,500
+0.25%
|
$1,284,000
$24.49 P/Share
|
Aug 12
2024
|
Arthur C Butcher |
BUY
Open market or private purchase
|
Direct |
1,315
+23.81%
|
$48,655
$37.99 P/Share
|
Jun 20
2024
|
Aimee S Weisner |
BUY
Grant, award, or other acquisition
|
Direct |
4,488
+22.62%
|
-
|
Jun 20
2024
|
Lilian Yansheng Zhou |
BUY
Grant, award, or other acquisition
|
Direct |
2,244
+32.93%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 17.7K shares |
---|---|
Open market or private purchase | 524K shares |
Exercise of conversion of derivative security | 2.61K shares |
Payment of exercise price or tax liability | 14.9K shares |
---|